Archive →
Daily Morning Briefing

Monday, 1 June 2026

Oil snaps back — Brent up ~2.4% — after a White House meeting to extend the Iran ceasefire broke up with no deal and a missile wounded Americans at a Kuwaiti air base · Washington bars any arrangement letting Tehran self-guarantee safe Hormuz passage · SoftBank overtakes Toyota as Japan’s most valuable company on the AI surge · Berkshire makes Greg Abel’s first big deal, a $8.5bn homebuilder buy.
Europe/Rome 06:00 · Markets open · pre-US-open · Risk-off tilt · war premium back
Live levels below are Monday-morning, pre-US-open (FT ticker, delayed ~15 min) shown against Friday 29 May closes. The tone has flipped from Friday’s record-chasing calm: oil is bid, Treasury yields are easing, and equity futures are barely higher as the Iran truce talks stall. Decisive data lands midweek — euro-area flash CPI (Tue) and US payrolls (Fri).

Top of the morning

FT portfolio signal · tied to your holdings

What FT flagged for your book

Macro / regime read. Two-sided this morning. The oil shock is back — Brent +2.4%, and Chevron’s CEO warned crude will jump over summer as supplies dwindle — but FT’s own analysis argues the Iran-war inflation hit will fall well short of the 2022 surge. More notable is the first cluster of credit-stress language in a while: private-credit outflows, a Bank of Canada correction warning, and an ECB hedge-fund/bond-instability flag. Not a severe trigger on the dashboard’s vol/credit lens yet — war-chest rules stay dormant — but it nudges the regime from “benign” toward “watch.”

Shelf single-names: no GLP-1 / Novo Nordisk / Eli Lilly / Vertex / UnitedHealth / Intuitive / payments single-name FT alerts in today’s window — Berkshire and the semis theme are the live ones. (Name-level alerts only surface here once FT routes them to this Gmail — see the iCloud→Gmail forwarding note if they stay sparse.)

Net: stay-the-course on the tech shelf with the AI-capex tailwind intact; treat the oil bid plus credit-stress whispers as a regime-watch flag, not a deployment trigger. Tuesday’s euro CPI and Friday’s US payrolls are the swing data.

Markets snapshot

Monday-morning, pre-US-open (FT live ticker, delayed ~15 min), shown against Friday 29 May closes. Risk-off tilt: oil bid, yields easing, equity futures flat-to-firmer.

InstrumentLast / refChange / context
S&P 500 (fut.)7,580 ref+0.22% · futures firmer pre-open
FTSE 100−0.16%
Shanghai Composite−0.12%
US 10-year Treasury~4.41%−0.67% in price-yield terms · safe-haven bid
EUR/USD~1.16−0.14% · dollar firmer
Brent crude~$93+2.41% · Iran/Hormuz premium back
WTI crude~$90tracking Brent higher
Gold (spot)~$4,500geopolitical hedge holding

Index reference levels carried from Friday’s close; today’s percentage moves are the live FT ticker. Brent/WTI levels are approximate from Friday’s prints plus today’s move.

Global markets & macro

The mood has cooled from Friday’s record-chasing exuberance. With the Iran ceasefire-extension meeting breaking up inconclusively, oil has reclaimed a chunk of its war premium — Brent up ~2.4% — and the classic risk-off plumbing kicked in: Treasury yields eased on a safe-haven bid (10-year back toward ~4.41%), the dollar firmed against the euro, and equity futures are only marginally higher. The structural story underneath is unchanged and still bullish: AI demand pushed SoftBank past Toyota atop the Japanese market, chip stocks are running at their fastest pace since the dotcom era, and the rally has broadened to drag dormant legacy-tech names along. But the cautionary chorus is getting louder — private-credit outflows, a Bank of Canada correction warning, an ECB flag on leveraged hedge-fund bond bets, and a record ~$8.3tn parked in money funds.

Rates politics is the macro sub-plot. Powell warned the Fed faces a stress test of its independence, and the first Bessent–Warsh breakfast reportedly took near-term cuts off the table, prompting Deutsche Bank to lift its 10-year yield forecast — a hawkish drift that today’s geopolitical bid is temporarily masking. The data calendar now matters more than ever: Tuesday’s euro-area flash CPI (April ran hot near 3.0% on energy) and Friday’s US payrolls (consensus ~89k, unemployment seen ~4.3%) frame the disinflation-versus-sticky-services debate just as oil threatens to reheat the energy component. Reassuringly, FT analysis argues the Iran-war inflation shock should fall short of the 2022 spike. In Europe, easyJet drew early interest from Castlelake, BP’s boardroom drama deepened with the fired chair hitting back, and EU–China trade friction escalated as Beijing pledged retaliation against any new restrictions.

Geopolitics & world news

The US–Iran track has gone sideways and tense. A White House meeting to extend the seven-week ceasefire ended with no conclusion as Trump sent deliberately mixed signals, and over the past day several Americans were wounded in a missile attack on a Kuwaiti air base. Crucially, Washington ruled out any deal that would let Tehran itself guarantee safe passage through the Strait of Hormuz — through which roughly a fifth of traded oil flows — while Qatar said a temporary mine-clearing transit fee remains negotiable. The market read is unambiguous: oil back on the front foot, gold steady, yields lower. Elsewhere in the region, Israel pushed deeper into Lebanon, capturing a Crusader-era castle in its latest advance.

Two further threads. In the Indo-Pacific, the Singapore defence forum set the tone: Hegseth talked up a budding US–Pakistan “friendship,” pledged to deter regional aggression alongside Japan and Korea, and delegates warned that AI now eclipses nuclear weapons as the field’s defining danger. And in Latin America, Colombia heads to a presidential run-off pitting a populist against the outgoing president’s candidate — one of several emerging-market votes worth watching this month. For the medical reader, two FT items stand out: a feature on whether Roche can reinvent the oncology franchise it once dominated, and a national-security piece on the West’s growing reliance on Chinese biotechs as blockbuster patents expire — both quiet but consequential for the drug-development landscape.

Today & week ahead (CET)